Literature DB >> 35731314

Management of patients with dysthyroid optic neuropathy treated with intravenous corticosteroids and/or orbital decompression surgery.

Sandra Rezar-Dreindl1, Andrea Papp1, Arnulf Baumann2, Thomas Neumayer1, Katharina Eibenberger1, Eva Stifter3, Ursula Schmidt-Erfurth1.   

Abstract

PURPOSE: To assess the characteristics and long-term outcomes of adult patients with dysthyroid optic neuropathy (DON) who underwent orbital decompression surgery and/or received intravenous (IV) methylprednisolone.
METHODS: Retrospective chart review of 98 eyes of 49 patients who were diagnosed and treated with bilateral DON between 2007 and 2018 at the Department of Ophthalmology and Optometry and Oral and Maxillofacial Surgery of the Medical University of Vienna.
RESULTS: The mean follow-up period was 4.1 ± 2.7 years. The most common presenting symptoms were eyelid and periorbital swelling (45%) representing active inflammation. Upgaze restriction was the most common clinical finding (73%). At time of diagnosis, the mean clinical activity score was 4 ± 1/4 ± 1 (right/left eye, respectively). Sixty-three percent (31/49) of the patients were treated both with IV methylprednisolone and underwent orbital decompression surgery, 22% (11/49) were treated with IV methylprednisolone alone and 14% (7/49) underwent surgical decompression only. Seventy-one percent (30/42) of the patients underwent 3-wall decompression. The mean reduction of proptosis in patients treated with both IV methylprednisolone and orbital decompression surgery was 4/5 mm. Mean of reduction in proptosis in patients receiving IV methylprednisolone only was 1/0 mm and in patients with surgical decompression only was 5/5 mm. Mean VA was 0.1 ± 0.5/0.1 ± 0.5 logMAR at baseline and 0.05 ± 0.7/0.05 ± 0.7 at final follow-up. In 92% (45/49), VA was preserved or improved at final follow-up.
CONCLUSIONS: The majority of patients with DON were treated both with IV corticosteroids and 3-wall decompression surgery. Vision could be successfully preserved in most cases and reduction of proptosis was achieved, especially after orbital decompression surgery.
© 2022. The Author(s).

Entities:  

Keywords:  Dysthyroid optic neuropathy; Intravenous corticosteroids; Orbital decompression surgery; Thyroid eye disease

Mesh:

Substances:

Year:  2022        PMID: 35731314      PMCID: PMC9581819          DOI: 10.1007/s00417-022-05732-4

Source DB:  PubMed          Journal:  Graefes Arch Clin Exp Ophthalmol        ISSN: 0721-832X            Impact factor:   3.535


  35 in total

1.  Surgical Treatment of Dysthyroid Optic Neuropathy: Long-Term Visual Outcomes with Comparison of 2-Wall versus 3-Wall Orbital Decompression.

Authors:  Safak Korkmaz; Onur Konuk
Journal:  Curr Eye Res       Date:  2015-04-02       Impact factor: 2.424

2.  Temporal hollowing and other adverse effects after lateral orbital wall decompression.

Authors:  Hans Olav Ueland; Olav H Haugen; Eyvind Rødahl
Journal:  Acta Ophthalmol       Date:  2016-06-08       Impact factor: 3.761

Review 3.  Orbital decompression for thyroid eye disease.

Authors:  Daniel B Rootman
Journal:  Surv Ophthalmol       Date:  2017-03-24       Impact factor: 6.048

4.  Randomized, single blind trial of intravenous versus oral steroid monotherapy in Graves' orbitopathy.

Authors:  George J Kahaly; Susanne Pitz; Gerhard Hommel; Manuela Dittmar
Journal:  J Clin Endocrinol Metab       Date:  2005-07-05       Impact factor: 5.958

5.  Randomized controlled trial of rituximab in patients with Graves' orbitopathy.

Authors:  Marius N Stan; James A Garrity; Barbara G Carranza Leon; Thapa Prabin; Elizabeth A Bradley; Rebecca S Bahn
Journal:  J Clin Endocrinol Metab       Date:  2014-10-24       Impact factor: 5.958

6.  Impact of smoking on the response to treatment of thyroid associated ophthalmopathy.

Authors:  A Eckstein; B Quadbeck; G Mueller; A W Rettenmeier; R Hoermann; K Mann; P Steuhl; J Esser
Journal:  Br J Ophthalmol       Date:  2003-06       Impact factor: 4.638

7.  The initial clinical characteristics of Graves' orbitopathy vary with age and sex.

Authors:  D L Kendler; J Lippa; J Rootman
Journal:  Arch Ophthalmol       Date:  1993-02

Review 8.  Medical Treatment of Graves' Orbitopathy.

Authors:  M Salvi; I Campi
Journal:  Horm Metab Res       Date:  2015-09-11       Impact factor: 2.936

Review 9.  Orbital decompression for thyroid eye disease: methods, outcomes, and complications.

Authors:  J M Jefferis; R K Jones; Z I Currie; J H Tan; S M Salvi
Journal:  Eye (Lond)       Date:  2017-12-15       Impact factor: 3.775

10.  Evolution of thyroid eye disease decompression-dysthyroid optic neuropathy.

Authors:  Andrea A Tooley; Kyle J Godfrey; Michael Kazim
Journal:  Eye (Lond)       Date:  2018-11-02       Impact factor: 3.775

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.